

Ref: FOI/GS/ID 4742

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

05 July 2018

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologics and Biosimilar prescribing.

You asked:

Could you please provide me with the following numbers of patients treated in the last 12 months (latest 12 months possible) with the following drugs for either Rheumatology, Dermatology or Gastroenterology departments.

Trust response:

Please see the below table.

Please note:

Figures are from April 17 to April 18.

Caveat: All patients on Rituximab will now be on Biosimilar, unless clinically indicated.

Number of patients treated	Rheumatology	Dermatology	Gastroenterology
TOTAL	1207	0	363
Abatacept [Orencia]	87	0	0
Adalimumab [Biosimilar]	0	0	0
Adalimumab [Humira]	292	0	128
Apremilast [Otezla]	4	0	0
Baricitinib [Olumiant]	2	0	0
Brodalumab [Kyntheum]	0	0	0
Certolizumab [Cimzia]	29	0	0
Dimethyl fumarate [Skilarence]	0	0	0
Etanercept [Enbrel]	118	0	0
Etanercept Biosimilar [Benepali or Erelzi]	192	0	0
Golimumab [Simponi]	137	0	6
Guselkumab [Tremfya]	0	0	0
Infliximab [Remicade]	17	0	9
Infliximab Biosimilar [Inflectra, Remsima or Flixabi]	52	0	165
Ixekizumab [Taltz]	0	0	0
Rituximab [Mabthera]	57	0	0
Rituximab Biosimilar [Rixathon or Truxima]	85	0	0
Sarilumab [Kevzara]	0	0	0
Secukinumab [Cosentyx]	38	0	0
Tocilizumab [Ro Actemra]	88	0	0
Tofacitinib [Xeljanz]	0	0	0
Ustekinumab [Stelara]	9	0	9
Vedolizumab [Entyvio]	0	0	46